Responses to Information on Treatments for Depression

Depressive Symptoms Clinical Trial

Official title:

Responses to Information on Treatments for Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04639765
• Other study ID #: 2020B0259
• Status: Completed
• Phase: N/A
• Start date: October 28, 2020
• Est. completion date: December 30, 2020

Study information

• Verified date: September 2021
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the impact of different messages about depression treatments.

Description:

Participants recruited through Amazon Mechanical Turk (MTurk) will complete a screening questionnaire and provided the opportunity to consent to participate. Upon entry to the study, eligible participants will complete several questionnaires pre- and post-randomization. Randomization will be to view either a video detailing a type of depression treatment (cognitive behavioral therapy, antidepressant medication, or the combination of both treatments) with and without an emphasis on personalization. A no video condition is also included.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: December 30, 2020
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• PHQ-9 Score indicating a history of elevated depression symptoms
• A high MTurk completion rate
• Must pass all attention checks inserted into the questionnaires
• No history of treatment for depression

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Depression
• Depressive Symptoms

Intervention

Other:
• CBT without Personalization
Intervention involves a video describing CBT without a message about personalization.
• CBT with Personalization
Intervention involves a video describing CBT with a message about personalization.
• ADM without Personalization
Intervention involves a video describing antidepressant medication without a message about personalization.
• ADM with Personalization
Intervention involves a video describing antidepressant medication with a message about personalization.
• Combined Treatment without Personalization
Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
• Combined Treatment with Personalization
Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.

Locations

Country	Name	City	State
United States	Psychology Building 1835 Neil Avenue	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Regressed change from baseline in expectations on the Credibility/Expectancy Questionnaire (CEQ)	The CEQ is a validated, commonly used measure assessing views of the credibility and expectations for benefit from a treatment.	Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
Primary	Regressed change from baseline in prognostic pessimism on an adapted version of the Perceptions of Depression Scale (PDS)	Measured using an adapted version of the PDS, a validated scale measuring general prognostic pessimism. Minor changes to wording were made to directly address the three different interventions in the study (CBT, ADM, Combined Treatment).	Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
Secondary	Regressed change from baseline in affect on the Positive and Negative Affectivity Scale (PANAS)	The PANAS is a widely used measure for positive and negative affect, and has been shown to be valid and reliable.	Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
Secondary	Regressed Change from baseline on the Beck Hopelessness Scale (BHS)	The BHS is the most widely used measure for hopelessness, and has been shown to be valid and reliable.	Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
Secondary	Regressed change from baseline in personal and perceived depression stigma on the Depression Stigma Scale (DSS).	The DSS is a valid and reliable measure for assessing personal and perceived stigma related to depression. The scale contains two subscales: personal stigma and perceived stigma.	Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
Secondary	Regressed change from baseline in beliefs on the etiology of depression on the Reasons for Depression Questionnaire (RFD).	The RFD is a valid and reliable measure for assessing one's beliefs on the etiology of depression.	Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
Secondary	Willingness to take a next step.	Participants are given the option to learn more about finding cognitive behavioral therapy, antidepressant medications, or combination therapy. Based on their responses, they are provided links to relevant websites. This approach has been adopted from traditional marketing research to assess participants' responsiveness to a message.	Up to 90 minutes to complete assessment. Assessed at the end of the study questionnaires (same day)